Literature DB >> 10933637

The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens.

A MacGowan1, C Rogers, K Bowker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10933637     DOI： 10.1093/jac/46.2.163

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  13 in total

Review 1.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

2.  Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin.

Authors:  Alison K Meagher; Alan Forrest; Axel Dalhoff; Heino Stass; Jerome J Schentag
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

3.  Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.

Authors:  Roland R Regoes; Camilla Wiuff; Renata M Zappala; Kim N Garner; Fernando Baquero; Bruce R Levin
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

4.  Pharmacokinetics of moxifloxacin in an infant with Mycoplasma hominis meningitis.

Authors:  Kevin M Watt; Matthew M Massaro; Brian Smith; Michael Cohen-Wolkowiez; Daniel K Benjamin; Matthew M Laughon
Journal:  Pediatr Infect Dis J       Date:  2012-02       Impact factor: 2.129

5.  Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients.

Authors:  M Dolores Sánchez Navarro; Carlos Coloma Milano; Aránzazu Zarzuelo Castañeda; M Luisa Sayalero Marinero; Amparo Sánchez-Navarro
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

6.  Cultivation of Neisseria gonorrhoeae in liquid media and determination of its in vitro susceptibilities to quinolones.

Authors:  Masaya Takei; Yuko Yamaguchi; Hideyuki Fukuda; Mitsuru Yasuda; Takashi Deguchi
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

7.  Correlation between in vitro and in vivo activities of GM 237354, a new sordarin derivative, against Candida albicans in an in vitro pharmacokinetic-pharmacodynamic model and influence of protein binding.

Authors:  P Aviles; C Falcoz; M J Guillén; R San Roman; F Gómez De Las Heras; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 8.  Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

9.  Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections.

Authors:  Yusuke Tanigawara; Mitsuo Kaku; Kyoichi Totsuka; Hiroyuki Tsuge; Atsushi Saito
Journal:  J Infect Chemother       Date:  2013-03-26       Impact factor: 2.211

Review 10.  Moxifloxacin: a review of its use in the management of bacterial infections.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.